NCT01998061

Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression

Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

There have been reports suggesting that continuous administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which gradual disease progression was observed after the establishment of clinical benefit from EGFR-TKIs. However, whether EGFR TKI with or without chemotherapy provides more survival benefit has not been formally evaluated.

Detailed description

We design this clinical trial to compare the efficacy of continuation of EGFR TKI with or without chemotherapy in patients beyond gradual progression.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	EGFR tyrosine kinase inhibitor	Arm A
DRUG	EGFR tyrosine kinase inhibitor with chemotherapy	Arm B

Timeline

• Start date: 2013-12-01
• Primary completion: 2015-06-01
• Completion: 2015-12-01
• First posted: 2013-11-28
• Last updated: 2013-12-20

Locations

1 site across 1 country: China